Biotech News

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix Pharmaceuticals Ltd (TLX)Telix Pharmaceuticals Ltd2026-10-19 05:30 ESTPartnership

MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 ( 211 At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.

Related news

TLXTelix Pharmaceuticals Ltd2026-06-02 11:00 EST

Telix and United Imaging Announce Strategic Theranostics Collaboration

TLXTelix Pharmaceuticals Ltd2026-04-13 10:30 EST

Telix and Regeneron Announce Strategic Radiopharma Collaboration

View all latest news

Telix Pharmaceuticals Ltd

Recent company news

TLXTelix Pharmaceuticals Ltd2026-10-20 22:10 EST

Telix Reports Third Quarter 2026 Financial Performance

TLXTelix Pharmaceuticals Ltd2026-10-19 05:30 EST

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

TLXTelix Pharmaceuticals Ltd2026-10-06 10:30 EST

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

TLXTelix Pharmaceuticals Ltd2026-09-21 00:55 EST

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

TLXTelix Pharmaceuticals Ltd2026-09-14 10:30 EST

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

Stock data

Close: 9.54 USD
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States